Andrea Brown
Family Medicine · Desoto, TXNPI 1831203207
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Novo Nordisk at 27.4% of the total. Reporting peaked in 2020 at $454 and has fallen 94.9% since, to $23 in 2025.
Across 73 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$337
- AstraZeneca$137
- Johnson & Johnson$127
- Amarin Pharma, Inc.$80
- Sanofi-aventis U.S. LLC$79
- Merck$65
- plus $404 from 12 others
Across 34 payments — averaging $1693.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$51K
- E.r. Squibb & Sons, L.L.C.$4K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Food & beverage$1,229100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $337 |
| AstraZeneca | 9 | $137 |
| Johnson & Johnson | 8 | $127 |
| Amarin Pharma, Inc. | 4 | $80 |
| Sanofi-aventis U.S. LLC | 5 | $79 |
| Merck | 5 | $65 |
| Boehringer Ingelheim | 4 | $58 |
| Amgen | 3 | $57 |
| AbbVie(2 entities) | 3 | $50 |
| Pfizer | 3 | $46 |
| Lilly USA, LLC | 3 | $43 |
| Novartis | 2 | $29 |
| Eisai Inc. | 1 | $24 |
| Conmed Corporation | 1 | $23 |
| Biotronik Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$114
How this compares
$1,229 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 11 | $357 |
| Montelukast Sodium | 18 | $160 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Desoto
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.